{
    "name": "daptomycin",
    "comment": "Rx",
    "other_names": [
        "Cubicin"
    ],
    "classes": [
        "Lipopeptides"
    ],
    "source": "https://reference.medscape.com/drug/cubicin-daptomycin-342576",
    "pregnancy": {
        "common": [
            "Limited published data on use in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage; no evidence of adverse developmental outcomes observed in animal reproduction studies"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Limited published data report that daptomycin is present in human milk at infant doses of 0.1% of maternal dose; there is no information on effects of daptomycin on breastfed infant or effects of daptomycin on milk production; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anaphylaxis/hypersensitivity reactions have been reported and may be life-threatening; discontinue the drug and institute appropriate therapy if allergic reaction occurs",
                "May cause eosinophilic pneumonia characterized by fever, cough, shortness of breath, and difficulty breathing; may result in progressive respiratory failure and is potentially fatal; prompt medical evaluation, and treatment should be discontinued immediately if signs/symptoms develop; treatment with systemic steroids is recommended",
                "Prolonged use may result in fungal or bacterial superinfection Perform susceptibility testing and rule out sequestered foci of infection if persisting or relapsing S. aureus bacteremia/endocarditis occurs",
                "Avoid use in pediatric patients <12 months; potential nervous system or muscular system effects",
                "Decreased efficacy reported in patients with moderate baseline renal impairment",
                "Fever, dyspnea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organizing pneumonia",
                "Drug reaction with eosinophilia and systemic symptoms (DRESS) reported postmarketing; patients who develop skin rash, fever, peripheral eosinophilia, and systemic organ (for example, hepatic, renal, pulmonary) impairment while receiving therapy should undergo medical evaluation; if DRESS suspected, discontinue therapy promptly and institute appropriate treatment",
                "Tubulointerstitial nephritis (TIN) reported post-marketing experience; patients who develop new or worsening renal impairment while receiving therapy should undergo medical evaluation; if TIN suspected, discontinue therapy promptly and institute appropriate treatment",
                "Cases of peripheral neuropathy have been reported during the daptomycin postmarketing experience; monitor and consider discontinuation",
                "Clinically relevant plasma concentrations of daptomycin reported to cause a significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay",
                "Prescribing in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit and increases risk of development of drug-resistant bacteria"
            ],
            "specific": [
                {
                    "type": "Clostridium difficile-associated diarrhea (CDAD)",
                    "description": [
                        "CDAD has been reported and may range in severity from mild diarrhea to fatal; CDAD must be considered in all patients who present with diarrhea following antibacterial use",
                        "Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents",
                        "Hypertoxin-producing strains of ",
                        "C. difficile ",
                        "cause increased morbidity and mortality, since these infections can be refractory to antimicrobial therapy and may require colectomy; CDAD must be considered in all patients who present with diarrhea following antibacterial use; careful medical history is necessary because CDAD has been reported to occur more than 2 months after administration of antibacterial agents",
                        "If CDAD is suspected/confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued",
                        "Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated"
                    ]
                },
                {
                    "type": "Myopathy and rhabdomyolysis",
                    "description": [
                        "Use cautiously in patients with peripheral neuropathies and myopathy; monitor for neuropathy and consider discontinuation",
                        "Discontinue with symptoms of myopathy and CPK >1000 U/L (>5x ULN), or no symptoms and CPK >2000 U/L (>10x ULN)",
                        "CPK elevations more prevalent if dosed more frequently than q24hr",
                        "Consider suspending statins during daptomycin therapy; theoretical risk of additive myopathy",
                        "Renal function and CPK should be monitored more frequently than once weekly in adult patients with renal impairment"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "daptomycin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "daptomycin decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "atorvastatin, daptomycin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "fluvastatin, daptomycin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lovastatin",
            "description": {
                "common": "lovastatin, daptomycin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitavastatin",
            "description": {
                "common": "pitavastatin, daptomycin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pravastatin",
            "description": {
                "common": "pravastatin, daptomycin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "rosuvastatin, daptomycin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "simvastatin",
            "description": {
                "common": "simvastatin, daptomycin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "daptomycin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin, daptomycin. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Tobramycin levels decrease and daptomycin levels increase when coadministered after single a dose."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Insomnia",
            "percent": "9.0"
        },
        {
            "name": "Pharyngolaryngeal pain",
            "percent": "8.0"
        },
        {
            "name": "Chest pain",
            "percent": "7.0"
        },
        {
            "name": "Elevated blood creatine phosphokinase",
            "percent": "7.0"
        },
        {
            "name": "Edema",
            "percent": "7.0"
        },
        {
            "name": "Abdominal pain",
            "percent": "6.0"
        },
        {
            "name": "Hypertension",
            "percent": "6.0"
        },
        {
            "name": "Pruritus",
            "percent": "6.0"
        },
        {
            "name": "Headache",
            "percent": "5.4"
        },
        {
            "name": "Diarrhea",
            "percent": "5.2"
        },
        {
            "name": "Sweating",
            "percent": "5.0"
        },
        {
            "name": "Bacteremia",
            "percent": "5.0"
        },
        {
            "name": "Sepsis",
            "percent": "5.0"
        },
        {
            "name": "Rash",
            "percent": "4.3"
        },
        {
            "name": "Abnormal LFTs",
            "percent": "3.0"
        },
        {
            "name": "UTI",
            "percent": "2.4"
        },
        {
            "name": "Hypotension",
            "percent": "2.4"
        },
        {
            "name": "Dizziness",
            "percent": "2.2"
        },
        {
            "name": "Dyspnea",
            "percent": "2.1"
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including angioedema",
            "percent": null
        },
        {
            "name": "drug rash with eosinophilia and systemic symptoms",
            "percent": null
        },
        {
            "name": "DRESS",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "hives",
            "percent": null
        },
        {
            "name": "shortness of breath",
            "percent": null
        },
        {
            "name": "difficulty swallowing",
            "percent": null
        },
        {
            "name": "truncal erythema",
            "percent": null
        },
        {
            "name": "and pulmonary eosinophilia",
            "percent": null
        },
        {
            "name": "consider treatment with systemic steroids",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Clostridium difficile",
            "percent": null
        },
        {
            "name": "associated diarrhea",
            "percent": null
        },
        {
            "name": "Musculoskeletal disorders",
            "percent": null
        },
        {
            "name": "myoglobin increased",
            "percent": null
        },
        {
            "name": "rhabdomyolysis",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "eosinophilic pneumonia",
            "percent": null
        },
        {
            "name": "organizing pneumonia",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Peripheral neuropathy",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Serious skin reactions",
            "percent": null
        },
        {
            "name": "including Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome and vesiculobullous rash",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "Special senses",
            "percent": null
        },
        {
            "name": "Visual disturbances",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "General and administration site conditions",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Acute kidney injury",
            "percent": null
        },
        {
            "name": "renal insufficiency",
            "percent": null
        },
        {
            "name": "and renal failure",
            "percent": null
        },
        {
            "name": "Skin and Subcutaneous Tissue Disorders",
            "percent": null
        },
        {
            "name": "Acute generalized exanthematous pustulosis",
            "percent": null
        },
        {
            "name": "epidermal necrolysis",
            "percent": null
        },
        {
            "name": "Tubulointerstitial nephritis",
            "percent": null
        },
        {
            "name": "Toxic epidermal necrolysis",
            "percent": null
        }
    ]
}